Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis
Status:
Terminated
Trial end date:
2019-12-11
Target enrollment:
Participant gender:
Summary
Part 1: To investigate the safety and tolerability of intravenous (IV) or subcutaneous (SC)
administration of a single dose of KHK4323 to Japanese or Caucasian healthy adult males in a
double-blind, placebo-controlled study.
Part 2: To investigate the safety and tolerability of intravenous (IV) administration of
repeated doses of KHK4323 to atopic dermatitis patients in a double-blind, placebo-controlled
study.